Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Mamoru Shiga; Naoaki Ban; Kazunobu Kuwabara; Hideharu Hata; Daishuke Ohira; Toshinori Nasu; Mashahiro Hiroshe; Rieko Kondou; Takahiko Horiguchi

Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Mamoru Shiga
, Naoaki Ban
, Kazunobu Kuwabara
, Hideharu Hata
, Daishuke Ohira
, Toshinori Nasu
, Mashahiro Hiroshe
, Rieko Kondou
, Takahiko Horiguchi

Research output: Contribution to journal › Article › peer-review

Abstract

Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV₁) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

Original language	English
Pages (from-to)	1254-1260
Number of pages	7
Journal	Japanese Journal of Chest Diseases
Volume	71
Issue number	12
Publication status	Published - 2012

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Cite this

@article{1d42a5d11f9e482da8b278601d7cac91,

title = "Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)",

abstract = "Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50\%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.",

author = "Mamoru Shiga and Naoaki Ban and Kazunobu Kuwabara and Hideharu Hata and Daishuke Ohira and Toshinori Nasu and Mashahiro Hiroshe and Rieko Kondou and Takahiko Horiguchi",

year = "2012",

language = "English",

volume = "71",

pages = "1254--1260",

journal = "Japanese Journal of Chest Diseases",

issn = "0385-3667",

publisher = "Kokuseido Publishing Co. Ltd",

number = "12",

}

TY - JOUR

T1 - Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

AU - Shiga, Mamoru

AU - Ban, Naoaki

AU - Kuwabara, Kazunobu

AU - Hata, Hideharu

AU - Ohira, Daishuke

AU - Nasu, Toshinori

AU - Hiroshe, Mashahiro

AU - Kondou, Rieko

AU - Horiguchi, Takahiko

PY - 2012

Y1 - 2012

N2 - Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

AB - Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.

UR - https://www.scopus.com/pages/publications/84871435003

UR - https://www.scopus.com/pages/publications/84871435003#tab=citedBy

M3 - Article

AN - SCOPUS:84871435003

SN - 0385-3667

VL - 71

SP - 1254

EP - 1260

JO - Japanese Journal of Chest Diseases

JF - Japanese Journal of Chest Diseases

IS - 12

ER -

Effects of pitavastatin in hypercholesterolemic patients with chronic obstructive pulmonary disease (COPD)

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this